Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Thanks to those that sent me the PM's.

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jan 07, 2022 10:19am

128 Views

Post# 34292619

RE:Thanks to those that sent me the PM's.

losingmyshirt wrote: It was obvious from the very beginning. Glad to see that you all agree.

If we all put him on Ignore, he will eventually disappear back down into his parents basement.

copy and paste a few to prove it

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale